FDA granted Fast Track designation to Zymeworks' investigational drug ZW191 for advanced/metastatic platinum-resistant ovarian cancer. Shares rose just over 3% to $24.73 in premarket trading. Fast Track can expedite development and review, improving the program's attractiveness to investors, but it is not an approval and value will remain contingent on clinical data and subsequent regulatory outcomes.
FDA granted Fast Track designation to Zymeworks' investigational drug ZW191 for advanced/metastatic platinum-resistant ovarian cancer. Shares rose just over 3% to $24.73 in premarket trading. Fast Track can expedite development and review, improving the program's attractiveness to investors, but it is not an approval and value will remain contingent on clinical data and subsequent regulatory outcomes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
